TNF-α gene expression in immune cells of patients with psoriasis and psoriatic arthritis
https://doi.org/10.21518/2079-701X-2022-16-13-6-10
Abstract
Introduction. Psoriatic disease is a heterogeneous inflammatory disease with different clinical manifestations, including plaque psoriasis and psoriatic arthritis. It has been shown that elevated levels of TNF-α are observed in both psoriatic arthritis and psoriasis. Studying the TNF-α gene expression pattern can help in the differential diagnosis between psoriatic arthritis and psoriasis.
The objective is to study the TNF-α gene expression pattern in blood mononuclear cells of patients with psoriatic arthritis and psoriasis for possible differential diagnosis between these two diseases.
Materials and methods. Mononuclear cells were isolated from the peripheral blood of 31 patients with plaque psoriasis, 45 patients with psoriatic arthritis and 20 healthy controls. The expression level of the TNF-α gene was analysed using a real-time PCR method.
Results and discussion. As a result of the comparison, the expression level of TNF-α in patients with psoriatic arthritis was found to be 179 times higher than the expression level in healthy volunteers. The expression level of TNF-α in patients with psoriasis was also significantly (106 times) higher than the expression level in healthy people. We managed to identify a significant difference between patients with psoriatic arthritis and psoriasis.
Conclusions. Patients with psoriasis in terms of TNF-α gene expression level in mononuclear cells are close to the condition of patients with psoriatic arthritis. A high level of TNF-α gene expression can become a marker of possible joint injury in patients with psoriasis and a signal to revise the therapeutic approach to a particular patient.
About the Authors
V. V. Sobolev
Center for Theoretical Problems of Physical and Chemical Pharmacology of Russian Academy of Sciences;
Mechnikov Scientific and Research Institute of Vaccines and Sera
Russian Federation
Russian Federation
Cand. Sci. (Biol.), Senior Researcher, 5a, Malyy Kazenny Lane, Moscow, 105064;
Senior Researcher, 30, Srednyaya Kalitnikovskaya St., Moscow, 109029
S. N. Chebysheva
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Cand. Sci. (Med.), Associate Professor, Associate Professor of Department of Children’s Diseases,
19, Bolshaya Pirogovskaya St., Moscow, 119435
N. A. Geppe
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Dr. Sci. (Med.), Professor, Head of the Department of Children’s Diseases, Clinical Institute of Children’s Health named after N.F. Filatov,
19, Bolshaya Pirogovskaya St., Moscow, 119435
K. V. Katkova
Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology of Moscow Health Department
Russian Federation
Russian Federation
Doctor,
20, Seleznevskaya St., Moscow, 127473
A. G. Soboleva
Center for Theoretical Problems of Physical and Chemical Pharmacology of Russian
Academy of Sciences;
Research Institute of Human Morphology
Russian Federation
Russian Federation
Cand. Sci. (Biol.), Senior Researcher, 30, Srednyaya Kalitnikovskaya St., Moscow, 109029;
Researcher, 3, Tsyurupy St., Moscow, 117418
I. M. Korsunskaya
Center for Theoretical Problems of Physical and Chemical Pharmacology of Russian Academy of Sciences;
Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology of Moscow Health Department
Russian Federation
Russian Federation
Dr. Sci. (Med.), Professor, Head of the Laboratory of Physicochemical and Genetic Problems of Dermatology, 30, Srednyaya Kalitnikovskaya St., Moscow, 109029;
Leading Researcher, 20, Seleznevskaya St., Moscow, 127473
References
1. Fantuzzi F., Del Giglio M., Gisondi P., Girolomoni G. Targeting tumor necrosis factor alpha in psoriasis and psoriatic arthritis. Expert Opin Ther Targets. 2008;12(9):1085–1096. https://doi.org/10.1517/14728222.12.9.1085.
2. Yamamoto T. Angiogenic and inflammatory properties of psoriatic arthritis. ISRN Dermatol. 2013:630620. https://doi.org/10.1155/2013/630620.
3. Marinoni B., Ceribelli A., Massarotti M.S., Selmi C. The Th17 axis in psoriatic disease: pathogenetic and therapeutic implications. Auto Immun Highlights. 2014;5(1):9–19. https://doi.org/10.1007/s13317-013-0057-4.
4. Sobolev V.V., Denisova E.V., Chebysheva S.N., Geppe N.A., Korsunskaya I.M. IL-6 Gene Expression as a Marker of Pathological State in Psoriasis and Psoriatic Arthritis. Bull Exp Biol Med. 2022;173(1):77–80. https://doi.org/10.1007/s10517-022-05497-0.
5. Sobolev V.V., Soboleva A.G., Denisova E.V., Pechatnikova E.A., Dvoryankova E., Korsunskaya I.M., Mezentsev A. Proteomic Studies of Psoriasis. Biomedicines. 2022;10(3):619. https://doi.org/10.3390/biomedicines10030619.
6. Li J., Liu L., Rui W., Li X., Xuan D., Zheng S. et al. New Interleukins in Psoriasis and Psoriatic Arthritis Patients: The Possible Roles of Interleukin-33 to Interleukin-38 in Disease Activities and Bone Erosions. Dermatology. 2017;233(1):37–46. https://doi.org/10.1159/000471798.
7. Przepiera-Będzak H., Fischer K., Brzosko M. Serum Interleukin-18, Fetuin-A, Soluble Intercellular Adhesion Molecule-1, and Endothelin-1 in Ankylosing Spondylitis, Psoriatic Arthritis, and SAPHO Syndrome. Int J Mol Sci. 2016;17(8):1255. https://doi.org/10.3390/ijms17081255.
8. Johansen C., Usher P.A., Kjellerup R.B., Lundsgaard D., Iversen L., Kragballe K. Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin. Br J Dermatol. 2009;160(2):319–324. https://doi.org/10.1111/j.1365-2133.2008.08902.x.
9. Sobolev V.V., Denisova E.V., Korsunskaya I.M. Alteration of STAT3 gene expression in psoriasis treatment. Meditsinskiy Sovet. 2020;(12):71–74. (In Russ.) https://doi.org/10.21518/2079-701X-2020-12-71-74.
10. Sobolev V., Nesterova A., Soboleva A., Mezentsev A., Dvoriankova E., Piruzyan A. et al. Analysis of PPARγ Signaling Activity in Psoriasis. Int J Mol Sci. 2021;22(16):8603. https://doi.org/10.3390/ijms22168603.
11. Sobolev V., Nesterova A., Soboleva A., Dvoriankova E., Piruzyan A., Mildzikhova D. et al. The Model of PPARγ-Downregulated Signaling in Psoriasis. PPAR Res. 2020:6529057. https://doi.org/10.1155/2020/6529057.
12. Sobolev V.V., Soboleva A.G., Potekaev N.N., Melnichenko O.O., Korsunskaya I.M., Artemyeva S.I. PPARγ gene expression analysis in psoriasis treatment. Meditsinskiy Sovet. 2021;(8):82–87. (In Russ.) https://doi.org/10.21518/2079-701X-2021-8-82-87.
13. Zheng Y., Danilenko D.M., Valdez P., Kasman I., Eastham-Anderson J., Wu J., Ouyang W. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature. 2007;445(7128):648–651. https://doi.org/10.1038/nature05505.
14. Sobolev V., Sakaniya L., Tretiakov A., Kokaeva Z., Naumova E., Rudko O. et al. Association of GA genotype of SNP rs4680 in COMT gene with psoriasis. Arch Dermatol Res. 2019;311(4):309–315. https://doi.org/10.1007/s00403-019-01904-1.
15. Mussi A., Bonifati C., Carducci M., D’Agosto G., Pimpinelli F., D’Urso D. et al. Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. J Biol Regul Homeost Agents. 1997;11(3):115–118. Available at: https://pubmed.ncbi.nlm.nih.gov/9498161/.
16. Nesterova A.P., Klimov E.A., Zharkova M., Sozin S., Sobolev V., Ivanikova N.V. et al. Disease Pathways: An Atlas of Human Disease Signaling Pathways. Amsterdam, New York: Elsevier; 2019. 732 p. https://doi.org/10.1016/C2018-0-00586-1.
17. Nesterova A.P., Klimov E.A., Zharkova M., Sozin S., Sobolev V., Ivanikova N.V. et al. Chapter 11 – Diseases of the skin and subcutaneous tissue. In: Nesterova A.P., Klimov E.A., Zharkova M., Sozin S., Sobolev V., Ivanikova N.V. et al. Disease Pathways: An Atlas of Human Disease Signaling Pathways. Amsterdam, New York: Elsevier; 2019, pp. 493–532. https://doi.org/10.1016/B978-0-12-817086-1.00011-7.
18. Sobolev V.V., Mezentsev A.V., Ziganshin R.H., Soboleva A.G., Denieva M., Korsunskaya I.M., Svitich O.A. LC-MS/MS analysis of lesional and normally looking psoriatic skin reveals significant changes in protein metabolism and RNA processing. PLoS ONE. 2021;16(5):e0240956. https://doi. org/10.1371/journal.pone.0240956.
19. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402–408. https://doi.org/10.1006/meth.2001.1262.
20. Akçali C., Guven E.H., Kirtak N., Inaloz H.S., Ozgoztasi O., Guvenc U. Serum concentrations of interleukin-2 and tumour necrosis factor-α under cyclosporine versus acitretin treatment in plaque-type psoriasis. J Int Med Res. 2014;42(5):1118–1122. https://doi.org/10.1177/0300060514539280.
21. Elias A.N., Nanda V.S., Pandian R. Serum TNF-alpha in psoriasis after treatment with propylthiouracil, an antithyroid thioureylene. BMC Dermatol. 2004;4:4. https://doi.org/10.1186/1471-5945-4-4.
22. Johansen C., Funding A.T., Otkjaer K., Kragballe K., Jensen U.B., Madsen M. et al. Protein expression of TNF-alpha in psoriatic skin is regulated at a posttranscriptional level by MAPK-activated protein kinase 2. J Immunol. 2006;176(3):1431–1438. https://doi.org/10.4049/jimmunol.176.3.1431.
Review
For citations:
Sobolev VV, Chebysheva SN, Geppe NA, Katkova KV, Soboleva AG, Korsunskaya IM. TNF-α gene expression in immune cells of patients with psoriasis and psoriatic arthritis. Meditsinskiy sovet = Medical Council. 2022;(13):6-10. (In Russ.) https://doi.org/10.21518/2079-701X-2022-16-13-6-10
Views:
448
Email this article 